Patents Assigned to Neurelis, Inc.
  • Publication number: 20230399311
    Abstract: The present disclosure relates to crystalline polymorphs of (R)-1-(1-(isoquinolin-5-ylsulfonyl)piperidin-4-yl)ethan-1-amine, salts thereof, pharmaceutical compositions thereof, pharmaceutical compositions comprising crystalline polymorphs of (R)-1-(1-(isoquinolin-5-ylsulfonyl)piperidin-4-yl)ethan-1-amine, salts thereof and methods of treatment of neurological conditions including cavernous angioma, cerebral aneurysm, stroke, subarachnoid hemorrhage, vasospasm after subarachnoid hemorrhage, traumatic brain injury, spinal cord injury, spinal cord injury stroke, seizures, hereditary hemorrhagic telangiectasis, cerebral arteriovascular malformations, sporadic cavernous angioma lesion, cerebral cavernous malformation, or combinations thereof, using the same.
    Type: Application
    Filed: June 9, 2023
    Publication date: December 14, 2023
    Applicants: BioAxone BioSciences, Inc., Neurelis, Inc.
    Inventors: Kenneth M. ROSEN, Matthew D. ABBINANTI, Lisa MCKERRACHER, Stuart MADDEN
  • Patent number: 11793786
    Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: October 24, 2023
    Assignee: Neurelis, Inc.
    Inventors: Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David F. Hale, Edward T. Maggio
  • Publication number: 20230301903
    Abstract: Compositions for intranasal delivery of olanzapine and methods for their use to treat various symptoms of schizophrenia, schizoaffective disorder, and bipolar disorder, such as acute agitation, mania, and mixed episodes. Intranasal olanzapine compositions comprise dodecyl maltoside to improve bioavailability of olanzapine and is administered via nasal mucosa to avoid direct systemic administration.
    Type: Application
    Filed: March 24, 2023
    Publication date: September 28, 2023
    Applicant: Neurelis, Inc.
    Inventor: Stuart MADDEN
  • Publication number: 20230104144
    Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
    Type: Application
    Filed: December 6, 2022
    Publication date: April 6, 2023
    Applicant: Neurelis, Inc.
    Inventors: Steve CARTT, David MEDEIROS, Garry Thomas GWOZDZ, Andrew LOXLEY, Mark MITCHNICK, David F. HALE, Edward T. MAGGIO
  • Publication number: 20220401456
    Abstract: Compositions for intranasal delivery of benzodiazepines, such as diazepam, midazolam, and lorazepam and methods for their use to treat and prevent seizures in pediatric subjects aged 2-5, inclusive. Compositions for rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration and methods of improving patient compliance with a prescribed treatment regimen.
    Type: Application
    Filed: June 10, 2022
    Publication date: December 22, 2022
    Applicant: Neurelis, Inc.
    Inventors: Adrian L. Rabinowicz, Enrique J. Carrazana
  • Publication number: 20220241187
    Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
    Type: Application
    Filed: April 15, 2022
    Publication date: August 4, 2022
    Applicant: Neurelis, Inc.
    Inventors: Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David Hale, Edward T. Maggio
  • Publication number: 20220218598
    Abstract: Compositions for intranasal delivery of benzodiazepines and methods for their use to treat and prevent seizures are provided. The compositions deliver rapid therapeutic onset with a decreased incidence and/or severity of adverse effects after administration. Additionally, use of the compositions for the treatment of seizure clusters increases the time to a second seizure and duration of the interseizure cluster interval.
    Type: Application
    Filed: January 7, 2022
    Publication date: July 14, 2022
    Applicant: Neurelis, Inc.
    Inventors: Sunita Misra, Enrique J. Carrazana, Adrian L. Rabinowicz, Stuart Madden, Edward T. Maggio
  • Publication number: 20220117887
    Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
    Type: Application
    Filed: June 2, 2021
    Publication date: April 21, 2022
    Applicant: Neurelis, Inc.
    Inventors: Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David Hale, Edward T. Maggio
  • Patent number: 11241414
    Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: February 8, 2022
    Assignee: Neurelis, Inc.
    Inventors: Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David F. Hale, Edward T. Maggio
  • Publication number: 20210299089
    Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
    Type: Application
    Filed: May 27, 2021
    Publication date: September 30, 2021
    Applicant: Neurelis, Inc.
    Inventors: Steve Cartt, David Medeiros, Garry Thomas Gwozdz, Andrew Loxley, Mark Mitchnick, David F. Hale, Edward T. Maggio